This retrospective study evaluating Bevacizumab (Avastin) treatment for severe pulmonary hypertension and high Cardiac output failure secondary to liver involvement in patients with hereditary hemorrhagic telangiectasia.

Trial Profile

This retrospective study evaluating Bevacizumab (Avastin) treatment for severe pulmonary hypertension and high Cardiac output failure secondary to liver involvement in patients with hereditary hemorrhagic telangiectasia.

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Nov 2017

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Pulmonary hypertension
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Nov 2017 New trial record
    • 24 Oct 2017 Results presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top